John Johnson - Mar 18, 2024 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
Director
Signature
/s/ Beth Hecht, as Attorney-in-Fact
Stock symbol
XERS
Transactions as of
Mar 18, 2024
Transactions value $
$429,044
Form type
4
Date filed
3/18/2024, 05:32 PM
Previous filing
Apr 1, 2024
Next filing
Jun 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Options Exercise $429K +216K +40.24% $1.99 751K Mar 18, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XERS Stock Option (Right to Buy) Options Exercise $0 -216K -100% $0.00* 0 Mar 18, 2024 Common Stock 216K $1.99 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options to purchase shares of Xeris Biopharma Holdings Inc. common stock fully vested on October 5, 2021.